APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phase I - IV Clinical Development Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Phase I - IV Clinical Development Services Market Outlook and Growth Opportunities 2026

30 December 2025212 pages

Choose your research edition.

Industry ResearchPhase I - IV Clinical Development Services Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Phase I - IV Clinical Development Services Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Phase I - IV Clinical Development Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phase I - IV Clinical Development Services Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Phase I - IV Clinical Development Services Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Phase I - IV Clinical Development Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Phase I - IV Clinical Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phase I - IV Clinical Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phase I - IV Clinical Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Phase I - IV Clinical Development Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Phase I - IV Clinical Development Services market include EPS Group, WuXi AppTec, Beijing Sun-novo Pharmaceutical Research, Elixir Clinical Research, Thermo Fisher Scientific, Dmedglobal, Worldwide Clinical Trial, Synteract and Syneos Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Phase I - IV Clinical Development Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phase I - IV Clinical Development Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phase I - IV Clinical Development Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Phase I - IV Clinical Development Services market.

Phase I - IV Clinical Development Services Segment by Company

EPS Group

WuXi AppTec

Beijing Sun-novo Pharmaceutical Research

Elixir Clinical Research

Thermo Fisher Scientific

Dmedglobal

Worldwide Clinical Trial

Synteract

Syneos Health

Sofpromed

Rho, Inc.

Profil

PPD

Parexel

OCT Clinical

LabCorp

ICON Plc

ICBio CRO

GVI CDS

Dynakin

CROS NT

Clinipace

Clinical Leader

Phase I - IV Clinical Development Services Segment by Type

Phase IIIb-IV

Phase II-III

Early Phase

Phase I - IV Clinical Development Services Segment by Application

Contract Research Organizations

Medical Device Companies

Pharmaceutical Companies

Phase I - IV Clinical Development Services Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Phase I - IV Clinical Development Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Phase I - IV Clinical Development Services key companies, revenue, market share, and recent developments.

3. To split the Phase I - IV Clinical Development Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Phase I - IV Clinical Development Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phase I - IV Clinical Development Services significant trends, drivers, influence factors in global and regions.

6. To analyze Phase I - IV Clinical Development Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phase I - IV Clinical Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phase I - IV Clinical Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phase I - IV Clinical Development Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phase I - IV Clinical Development Services industry.

Chapter 3: Detailed analysis of Phase I - IV Clinical Development Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Phase I - IV Clinical Development Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Phase I - IV Clinical Development Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phase I - IV Clinical Development Services Industry Trends Table 2. Phase I - IV Clinical Development Services Industry Drivers Table 3. Phase I - IV Clinical Development Services Industry Opportunities and Challenges Table 4. Phase I - IV Clinical Development Services Industry Restraints Table 5. Global Phase I - IV Clinical Development Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phase I - IV Clinical Development Services Revenue Share by Company (2021-2026) Table 7. Global Phase I - IV Clinical Development Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Phase I - IV Clinical Development Services Key Company Manufacturing Base & Headquarters Table 9. Global Phase I - IV Clinical Development Services Company, Product Type & Application Table 10. Global Phase I - IV Clinical Development Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Phase I - IV Clinical Development Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Phase IIIb-IV Table 15. Significant Companies of Phase II-III Table 16. Significant Companies of Early Phase Table 17. Global Phase I - IV Clinical Development Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Phase I - IV Clinical Development Services Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Phase I - IV Clinical Development Services Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Phase I - IV Clinical Development Services Sales Value Share by Type (2021-2026) Table 21. Global Phase I - IV Clinical Development Services Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Contract Research Organizations Table 23. Significant Companies of Medical Device Companies Table 24. Significant Companies of Pharmaceutical Companies Table 25. Global Phase I - IV Clinical Development Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Phase I - IV Clinical Development Services Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Phase I - IV Clinical Development Services Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Phase I - IV Clinical Development Services Sales Value Share by Application (2021-2026) Table 29. Global Phase I - IV Clinical Development Services Sales Value Share by Application (2027-2032) Table 30. Global Phase I - IV Clinical Development Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Phase I - IV Clinical Development Services Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Phase I - IV Clinical Development Services Sales Value Share by Region (2021-2026) Table 33. Global Phase I - IV Clinical Development Services Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Phase I - IV Clinical Development Services Sales Value Share by Region (2027-2032) Table 35. Global Phase I - IV Clinical Development Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Phase I - IV Clinical Development Services Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Phase I - IV Clinical Development Services Sales Value Market Share by Country (2021-2026) Table 38. Global Phase I - IV Clinical Development Services Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Phase I - IV Clinical Development Services Sales Value Market Share by Country (2027-2032) Table 40. EPS Group Company Information Table 41. EPS Group Business Overview Table 42. EPS Group Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. EPS Group Phase I - IV Clinical Development Services Product Portfolio Table 44. EPS Group Recent Development Table 45. WuXi AppTec Company Information Table 46. WuXi AppTec Business Overview Table 47. WuXi AppTec Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. WuXi AppTec Phase I - IV Clinical Development Services Product Portfolio Table 49. WuXi AppTec Recent Development Table 50. Beijing Sun-novo Pharmaceutical Research Company Information Table 51. Beijing Sun-novo Pharmaceutical Research Business Overview Table 52. Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product Portfolio Table 54. Beijing Sun-novo Pharmaceutical Research Recent Development Table 55. Elixir Clinical Research Company Information Table 56. Elixir Clinical Research Business Overview Table 57. Elixir Clinical Research Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Elixir Clinical Research Phase I - IV Clinical Development Services Product Portfolio Table 59. Elixir Clinical Research Recent Development Table 60. Thermo Fisher Scientific Company Information Table 61. Thermo Fisher Scientific Business Overview Table 62. Thermo Fisher Scientific Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Thermo Fisher Scientific Phase I - IV Clinical Development Services Product Portfolio Table 64. Thermo Fisher Scientific Recent Development Table 65. Dmedglobal Company Information Table 66. Dmedglobal Business Overview Table 67. Dmedglobal Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Dmedglobal Phase I - IV Clinical Development Services Product Portfolio Table 69. Dmedglobal Recent Development Table 70. Worldwide Clinical Trial Company Information Table 71. Worldwide Clinical Trial Business Overview Table 72. Worldwide Clinical Trial Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Worldwide Clinical Trial Phase I - IV Clinical Development Services Product Portfolio Table 74. Worldwide Clinical Trial Recent Development Table 75. Synteract Company Information Table 76. Synteract Business Overview Table 77. Synteract Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Synteract Phase I - IV Clinical Development Services Product Portfolio Table 79. Synteract Recent Development Table 80. Syneos Health Company Information Table 81. Syneos Health Business Overview Table 82. Syneos Health Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Syneos Health Phase I - IV Clinical Development Services Product Portfolio Table 84. Syneos Health Recent Development Table 85. Sofpromed Company Information Table 86. Sofpromed Business Overview Table 87. Sofpromed Phase I - IV Clinical Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sofpromed Phase I - IV Clinical Development Services Product Portfolio Table 89. Sofpromed Recent Development Table 90. Rho, Inc. Company Information Table 91. Rho, Inc. Business Overview Table 92. Rho, Inc. Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Rho, Inc. Phase I - IV Clinical Development Services Product Portfolio Table 94. Rho, Inc. Recent Development Table 95. Profil Company Information Table 96. Profil Business Overview Table 97. Profil Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Profil Phase I - IV Clinical Development Services Product Portfolio Table 99. Profil Recent Development Table 100. PPD Company Information Table 101. PPD Business Overview Table 102. PPD Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. PPD Phase I - IV Clinical Development Services Product Portfolio Table 104. PPD Recent Development Table 105. Parexel Company Information Table 106. Parexel Business Overview Table 107. Parexel Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Parexel Phase I - IV Clinical Development Services Product Portfolio Table 109. Parexel Recent Development Table 110. OCT Clinical Company Information Table 111. OCT Clinical Business Overview Table 112. OCT Clinical Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. OCT Clinical Phase I - IV Clinical Development Services Product Portfolio Table 114. OCT Clinical Recent Development Table 115. LabCorp Company Information Table 116. LabCorp Business Overview Table 117. LabCorp Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. LabCorp Phase I - IV Clinical Development Services Product Portfolio Table 119. LabCorp Recent Development Table 120. ICON Plc Company Information Table 121. ICON Plc Business Overview Table 122. ICON Plc Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. ICON Plc Phase I - IV Clinical Development Services Product Portfolio Table 124. ICON Plc Recent Development Table 125. ICBio CRO Company Information Table 126. ICBio CRO Business Overview Table 127. ICBio CRO Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. ICBio CRO Phase I - IV Clinical Development Services Product Portfolio Table 129. ICBio CRO Recent Development Table 130. GVI CDS Company Information Table 131. GVI CDS Business Overview Table 132. GVI CDS Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. GVI CDS Phase I - IV Clinical Development Services Product Portfolio Table 134. GVI CDS Recent Development Table 135. Dynakin Company Information Table 136. Dynakin Business Overview Table 137. Dynakin Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Dynakin Phase I - IV Clinical Development Services Product Portfolio Table 139. Dynakin Recent Development Table 140. CROS NT Company Information Table 141. CROS NT Business Overview Table 142. CROS NT Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. CROS NT Phase I - IV Clinical Development Services Product Portfolio Table 144. CROS NT Recent Development Table 145. Clinipace Company Information Table 146. Clinipace Business Overview Table 147. Clinipace Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Clinipace Phase I - IV Clinical Development Services Product Portfolio Table 149. Clinipace Recent Development Table 150. Clinical Leader Company Information Table 151. Clinical Leader Business Overview Table 152. Clinical Leader Phase I - IV Clinical Development Services Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Clinical Leader Phase I - IV Clinical Development Services Product Portfolio Table 154. Clinical Leader Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Phase I - IV Clinical Development Services Product Image Figure 2. Global Phase I - IV Clinical Development Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phase I - IV Clinical Development Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Phase I - IV Clinical Development Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Phase IIIb-IV Image Figure 8. Phase II-III Image Figure 9. Early Phase Image Figure 10. Global Phase I - IV Clinical Development Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Phase I - IV Clinical Development Services Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Phase I - IV Clinical Development Services Sales Value Share by Type (2021-2032) Figure 13. Contract Research Organizations Image Figure 14. Medical Device Companies Image Figure 15. Pharmaceutical Companies Image Figure 16. Global Phase I - IV Clinical Development Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Phase I - IV Clinical Development Services Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Phase I - IV Clinical Development Services Sales Value Share by Application (2021-2032) Figure 19. Global Phase I - IV Clinical Development Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Phase I - IV Clinical Development Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Phase I - IV Clinical Development Services Sales Value (2021-2032) & (US$ Million) Figure 22. North America Phase I - IV Clinical Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Phase I - IV Clinical Development Services Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Phase I - IV Clinical Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Phase I - IV Clinical Development Services Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Phase I - IV Clinical Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Phase I - IV Clinical Development Services Sales Value (2021-2032) & (US$ Million) Figure 28. South America Phase I - IV Clinical Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Phase I - IV Clinical Development Services Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Phase I - IV Clinical Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Phase IIIb-IV
  • Phase II-III
  • Early Phase
Applications
  • Contract Research Organizations
  • Medical Device Companies
  • Pharmaceutical Companies
Companies covered
  • EPS Group
  • WuXi AppTec
  • Beijing Sun-novo Pharmaceutical Research
  • Elixir Clinical Research
  • Thermo Fisher Scientific
  • Dmedglobal
  • Worldwide Clinical Trial
  • Synteract
  • Syneos Health
  • Sofpromed
  • Rho, Inc.
  • Profil
  • PPD
  • Parexel
  • OCT Clinical
  • LabCorp
  • ICON Plc
  • ICBio CRO
  • GVI CDS
  • Dynakin
  • CROS NT
  • Clinipace
  • Clinical Leader

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phase I - IV Clinical Development Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phase I - IV Clinical Development Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Phase I - IV Clinical Development Services Market Dynamics
  1. 2.1 Phase I - IV Clinical Development Services Industry Trends
  2. 2.2 Phase I - IV Clinical Development Services Industry Drivers
  3. 2.3 Phase I - IV Clinical Development Services Industry Opportunities and Challenges
  4. 2.4 Phase I - IV Clinical Development Services Industry Restraints
3 Phase I - IV Clinical Development Services Market by Company
  1. 3.1 Global Phase I - IV Clinical Development Services Company Revenue Ranking in 2025
  2. 3.2 Global Phase I - IV Clinical Development Services Revenue by Company (2021-2026)
  3. 3.3 Global Phase I - IV Clinical Development Services Company Ranking (2024-2026)
  4. 3.4 Global Phase I - IV Clinical Development Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Phase I - IV Clinical Development Services Company Product Type and Application
  6. 3.6 Global Phase I - IV Clinical Development Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Phase I - IV Clinical Development Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Phase I - IV Clinical Development Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Phase I - IV Clinical Development Services Market by Type
  1. 4.1 Phase I - IV Clinical Development Services Type Introduction
  2. 4.1.1 Phase IIIb-IV
  3. 4.1.2 Phase II-III
  4. 4.1.3 Early Phase
  5. 4.2 Global Phase I - IV Clinical Development Services Sales Value by Type
  6. 4.2.1 Global Phase I - IV Clinical Development Services Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Phase I - IV Clinical Development Services Sales Value by Type (2021-2032)
  8. 4.2.3 Global Phase I - IV Clinical Development Services Sales Value Share by Type (2021-2032)
5 Phase I - IV Clinical Development Services Market by Application
  1. 5.1 Phase I - IV Clinical Development Services Application Introduction
  2. 5.1.1 Contract Research Organizations
  3. 5.1.2 Medical Device Companies
  4. 5.1.3 Pharmaceutical Companies
  5. 5.2 Global Phase I - IV Clinical Development Services Sales Value by Application
  6. 5.2.1 Global Phase I - IV Clinical Development Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Phase I - IV Clinical Development Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Phase I - IV Clinical Development Services Sales Value Share by Application (2021-2032)
6 Phase I - IV Clinical Development Services Regional Value Analysis
  1. 6.1 Global Phase I - IV Clinical Development Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phase I - IV Clinical Development Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Phase I - IV Clinical Development Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Phase I - IV Clinical Development Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phase I - IV Clinical Development Services Sales Value (2021-2032)
  7. 6.3.2 North America Phase I - IV Clinical Development Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Phase I - IV Clinical Development Services Sales Value (2021-2032)
  10. 6.4.2 Europe Phase I - IV Clinical Development Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Phase I - IV Clinical Development Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Phase I - IV Clinical Development Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Phase I - IV Clinical Development Services Sales Value (2021-2032)
  16. 6.6.2 South America Phase I - IV Clinical Development Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Phase I - IV Clinical Development Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Phase I - IV Clinical Development Services Sales Value Share by Country, 2025 VS 2032
7 Phase I - IV Clinical Development Services Country-level Value Analysis
  1. 7.1 Global Phase I - IV Clinical Development Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phase I - IV Clinical Development Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Phase I - IV Clinical Development Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Phase I - IV Clinical Development Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Phase I - IV Clinical Development Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Phase I - IV Clinical Development Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Phase I - IV Clinical Development Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 EPS Group
  2. 8.1.1 EPS Group Company Information
  3. 8.1.2 EPS Group Business Overview
  4. 8.1.3 EPS Group Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 EPS Group Phase I - IV Clinical Development Services Product Portfolio
  6. 8.1.5 EPS Group Recent Developments
  7. 8.2 WuXi AppTec
  8. 8.2.1 WuXi AppTec Company Information
  9. 8.2.2 WuXi AppTec Business Overview
  10. 8.2.3 WuXi AppTec Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 WuXi AppTec Phase I - IV Clinical Development Services Product Portfolio
  12. 8.2.5 WuXi AppTec Recent Developments
  13. 8.3 Beijing Sun-novo Pharmaceutical Research
  14. 8.3.1 Beijing Sun-novo Pharmaceutical Research Company Information
  15. 8.3.2 Beijing Sun-novo Pharmaceutical Research Business Overview
  16. 8.3.3 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product Portfolio
  18. 8.3.5 Beijing Sun-novo Pharmaceutical Research Recent Developments
  19. 8.4 Elixir Clinical Research
  20. 8.4.1 Elixir Clinical Research Company Information
  21. 8.4.2 Elixir Clinical Research Business Overview
  22. 8.4.3 Elixir Clinical Research Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Elixir Clinical Research Phase I - IV Clinical Development Services Product Portfolio
  24. 8.4.5 Elixir Clinical Research Recent Developments
  25. 8.5 Thermo Fisher Scientific
  26. 8.5.1 Thermo Fisher Scientific Company Information
  27. 8.5.2 Thermo Fisher Scientific Business Overview
  28. 8.5.3 Thermo Fisher Scientific Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Thermo Fisher Scientific Phase I - IV Clinical Development Services Product Portfolio
  30. 8.5.5 Thermo Fisher Scientific Recent Developments
  31. 8.6 Dmedglobal
  32. 8.6.1 Dmedglobal Company Information
  33. 8.6.2 Dmedglobal Business Overview
  34. 8.6.3 Dmedglobal Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dmedglobal Phase I - IV Clinical Development Services Product Portfolio
  36. 8.6.5 Dmedglobal Recent Developments
  37. 8.7 Worldwide Clinical Trial
  38. 8.7.1 Worldwide Clinical Trial Company Information
  39. 8.7.2 Worldwide Clinical Trial Business Overview
  40. 8.7.3 Worldwide Clinical Trial Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Worldwide Clinical Trial Phase I - IV Clinical Development Services Product Portfolio
  42. 8.7.5 Worldwide Clinical Trial Recent Developments
  43. 8.8 Synteract
  44. 8.8.1 Synteract Company Information
  45. 8.8.2 Synteract Business Overview
  46. 8.8.3 Synteract Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Synteract Phase I - IV Clinical Development Services Product Portfolio
  48. 8.8.5 Synteract Recent Developments
  49. 8.9 Syneos Health
  50. 8.9.1 Syneos Health Company Information
  51. 8.9.2 Syneos Health Business Overview
  52. 8.9.3 Syneos Health Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Syneos Health Phase I - IV Clinical Development Services Product Portfolio
  54. 8.9.5 Syneos Health Recent Developments
  55. 8.10 Sofpromed
  56. 8.10.1 Sofpromed Company Information
  57. 8.10.2 Sofpromed Business Overview
  58. 8.10.3 Sofpromed Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sofpromed Phase I - IV Clinical Development Services Product Portfolio
  60. 8.10.5 Sofpromed Recent Developments
  61. 8.11 Rho, Inc.
  62. 8.11.1 Rho, Inc. Company Information
  63. 8.11.2 Rho, Inc. Business Overview
  64. 8.11.3 Rho, Inc. Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Rho, Inc. Phase I - IV Clinical Development Services Product Portfolio
  66. 8.11.5 Rho, Inc. Recent Developments
  67. 8.12 Profil
  68. 8.12.1 Profil Company Information
  69. 8.12.2 Profil Business Overview
  70. 8.12.3 Profil Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Profil Phase I - IV Clinical Development Services Product Portfolio
  72. 8.12.5 Profil Recent Developments
  73. 8.13 PPD
  74. 8.13.1 PPD Company Information
  75. 8.13.2 PPD Business Overview
  76. 8.13.3 PPD Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  77. 8.13.4 PPD Phase I - IV Clinical Development Services Product Portfolio
  78. 8.13.5 PPD Recent Developments
  79. 8.14 Parexel
  80. 8.14.1 Parexel Company Information
  81. 8.14.2 Parexel Business Overview
  82. 8.14.3 Parexel Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Parexel Phase I - IV Clinical Development Services Product Portfolio
  84. 8.14.5 Parexel Recent Developments
  85. 8.15 OCT Clinical
  86. 8.15.1 OCT Clinical Company Information
  87. 8.15.2 OCT Clinical Business Overview
  88. 8.15.3 OCT Clinical Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  89. 8.15.4 OCT Clinical Phase I - IV Clinical Development Services Product Portfolio
  90. 8.15.5 OCT Clinical Recent Developments
  91. 8.16 LabCorp
  92. 8.16.1 LabCorp Company Information
  93. 8.16.2 LabCorp Business Overview
  94. 8.16.3 LabCorp Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  95. 8.16.4 LabCorp Phase I - IV Clinical Development Services Product Portfolio
  96. 8.16.5 LabCorp Recent Developments
  97. 8.17 ICON Plc
  98. 8.17.1 ICON Plc Company Information
  99. 8.17.2 ICON Plc Business Overview
  100. 8.17.3 ICON Plc Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ICON Plc Phase I - IV Clinical Development Services Product Portfolio
  102. 8.17.5 ICON Plc Recent Developments
  103. 8.18 ICBio CRO
  104. 8.18.1 ICBio CRO Company Information
  105. 8.18.2 ICBio CRO Business Overview
  106. 8.18.3 ICBio CRO Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  107. 8.18.4 ICBio CRO Phase I - IV Clinical Development Services Product Portfolio
  108. 8.18.5 ICBio CRO Recent Developments
  109. 8.19 GVI CDS
  110. 8.19.1 GVI CDS Company Information
  111. 8.19.2 GVI CDS Business Overview
  112. 8.19.3 GVI CDS Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  113. 8.19.4 GVI CDS Phase I - IV Clinical Development Services Product Portfolio
  114. 8.19.5 GVI CDS Recent Developments
  115. 8.20 Dynakin
  116. 8.20.1 Dynakin Company Information
  117. 8.20.2 Dynakin Business Overview
  118. 8.20.3 Dynakin Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Dynakin Phase I - IV Clinical Development Services Product Portfolio
  120. 8.20.5 Dynakin Recent Developments
  121. 8.21 CROS NT
  122. 8.21.1 CROS NT Company Information
  123. 8.21.2 CROS NT Business Overview
  124. 8.21.3 CROS NT Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  125. 8.21.4 CROS NT Phase I - IV Clinical Development Services Product Portfolio
  126. 8.21.5 CROS NT Recent Developments
  127. 8.22 Clinipace
  128. 8.22.1 Clinipace Company Information
  129. 8.22.2 Clinipace Business Overview
  130. 8.22.3 Clinipace Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Clinipace Phase I - IV Clinical Development Services Product Portfolio
  132. 8.22.5 Clinipace Recent Developments
  133. 8.23 Clinical Leader
  134. 8.23.1 Clinical Leader Company Information
  135. 8.23.2 Clinical Leader Business Overview
  136. 8.23.3 Clinical Leader Phase I - IV Clinical Development Services Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Clinical Leader Phase I - IV Clinical Development Services Product Portfolio
  138. 8.23.5 Clinical Leader Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst